SRF and skin basal cell carcinoma: Along the same line, Whitson et al. demonstrated that serum response factor (SRF) and the coactivator megakaryoblastic leukemia 1 (MLK1) together with GLI1 activation drives non-canonical Hedgehog signaling and induces SMOi resistance in BCC patients [31].